The results suggest that GSK3036656 could become a component of new, simpler treatment regimens for TB, and its novel mechanism of action raises ... sickle cell disease, Casgevy, has been given ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic portfolio ...

Vertex offers up to $70,000 in fertility services assistance for patients undergoing Casgevy treatment ... VRTX Price Action: Vertex stock is down 1.41% at $418.29 at publication Thursday.